$48.04
0.12%
Nasdaq, Mon, Nov 25 2024
ISIN
US05455M1009
Symbol
AVRO
Sector
Industry

AVROBIO Inc Stock price

$48.04
+9.30 24.01% 1M
+29.92 165.12% 6M
+31.72 194.36% YTD
+33.04 220.27% 1Y
-7.04 12.78% 3Y
-144.32 75.03% 5Y
-326.36 87.17% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.06 0.12%
ISIN
US05455M1009
Symbol
AVRO
Sector
Industry

Key metrics

Market capitalization $708.72m
Enterprise Value $552.60m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 4.71
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-48.30m
Free Cash Flow (TTM) Free Cash Flow $-50.44m
Cash position $159.10m
EPS (TTM) EPS $-9.73
P/E forward negative
Short interest 0.45%
Show more

Is AVROBIO Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

AVROBIO Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a AVROBIO Inc forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a AVROBIO Inc forecast:

Buy
100%

Financial data from AVROBIO Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.69 0.69
86% 86%
-
-0.69 -0.69
86% 86%
-
- Selling and Administrative Expenses 21 21
7% 7%
-
- Research and Development Expense 26 26
55% 55%
-
-48 -48
42% 42%
-
- Depreciation and Amortization 0.69 0.69
86% 86%
-
EBIT (Operating Income) EBIT -48 -48
45% 45%
-
Net Profit -46 -46
1,024% 1,024%
-

In millions USD.

Don't miss a Thing! We will send you all news about AVROBIO Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AVROBIO Inc Stock News

Neutral
InvestorPlace
5 months ago
Avrobio (NASDAQ: AVRO ) stock is on the move Thursday as the company is preparing for two major events taking place today. The first thing to note is that Avrobio is getting ready to undergo a merger with Tectonic Therapeutic.
Neutral
Business Wire
6 months ago
WATERTOWN, Mass.--(BUSINESS WIRE)--Tectonic Therapeutic, Inc. (“Tectonic”), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, today announced the appointment of Daniel Lochner as Chief Financial Officer of Tectonic. “Dan is an experienced public-company CFO who will add significant financial expertise to our team,” said Alise Reic...

Company Profile

Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firms clinical-stage programs include Fabry disease, Gaucher disease and cystinosis . The company was founded by Geoff Mackay in 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Alise Reicin
Employees 13
Founded 2015
Website tectonictx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today